Key Takeaways From ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18
Maintaining Buy Rating on ADMA Biologics Amid Auditor Resignation: Confidence in Fiscal Health and Compliance
ADMA Biologics (ADMA) Receives a Buy From Mizuho Securities
ADMA Biologics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target
Buy Rating Affirmed for ADMA Biologics Amid Strong Financial Performance and Promising R&D Prospects
ADMA Biologics Price Target Raised to $20.00/Share From $15.00 by Cantor Fitzgerald
ADMA Biologics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
ADMA Biologics Analyst Ratings
ADMA Biologics Analyst Ratings
ADMA Biologics Analyst Ratings
Strong Financial Performance and Growth Prospects Affirm Buy Rating for ADMA Biologics
ADMA Biologics Analyst Ratings
ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed With Enhanced Price Target
ADMA Biologics Analyst Ratings
Buy Rating Affirmed for ADMA Biologics Amidst Strong Financial Growth and Positive Long-Term Outlook
ADMA Biologics Analyst Ratings
HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $6